APA (7th ed.) Citation

S, M., Y, K., Y, M., K, N., M, Y., A, H., . . . M, K. (2026). Prognostic impact of procarbazine in R-MPV followed by reduced-dose whole-brain radiotherapy and cytarabine for primary central nervous system lymphoma. Leukemia & lymphoma, 67(3), 638. https://doi.org/10.1080/10428194.2025.2604305

Chicago Style (17th ed.) Citation

S, Matsumoto, Kurihara Y, Masuda Y, Nara K, Yuasa M, Honda A, Takada T, and Kurokawa M. "Prognostic Impact of Procarbazine in R-MPV Followed by Reduced-dose Whole-brain Radiotherapy and Cytarabine for Primary Central Nervous System Lymphoma." Leukemia & Lymphoma 67, no. 3 (2026): 638. https://doi.org/10.1080/10428194.2025.2604305.

MLA (9th ed.) Citation

S, Matsumoto, et al. "Prognostic Impact of Procarbazine in R-MPV Followed by Reduced-dose Whole-brain Radiotherapy and Cytarabine for Primary Central Nervous System Lymphoma." Leukemia & Lymphoma, vol. 67, no. 3, 2026, p. 638, https://doi.org/10.1080/10428194.2025.2604305.